These 10 “Crisis-Proof” Funds Yield Up to 10% (with 17% upside)

Our Archive

Search completed

After watching the S&P 500 crash, then levitate, over the past seven months, I’ve come to one conclusion: high-yield closed-end funds (CEFs) are disrespected now—and that makes them a great contrarian buy.

Sure, some CEFs are cheap for a reason (I’m looking at you, energy funds). But there are plenty of undervalued winners, too. And plenty of CEFs have crushed the market this year, including 10 that have returned more than 8%. This top-10 list, which I’ll show you below, includes CEFs that have doubled, tripled—and even quadrupled the S&P 500’s 4% return.

What’s more, these funds all have one thing in common that sets them up for even bigger gains: strong management, proving once again that who manages your money is just as important as what you invest in—especially if you’re looking to boost your portfolio’s income stream with the 7% (or higher) dividends the typical CEF throws off.… Read more

Read More

If you’re like pretty well everyone else, you’re closely watching Gilead Sciences (GILD), creator of remdesivir, a drug that, last week, showed progress in treating the coronavirus in a US government study.

But does that make Gilead a good stock to buy now, particularly if you’re focused on income? Let’s take a look.

First up, unlike many other stocks these days, Gilead boasts a safe payout, with the dividend accounting for just 38% of free cash flow in the last 12 months. And the company has increased its dividend every year since initiating it in 2015:

A Reliable Dividend

It’s on the current-yield front where the dividend story starts to fray.… Read more

Read More

If you’re like pretty well everyone else, you’re closely watching Gilead Sciences (GILD), creator of remdesivir, a drug that, last week, showed progress in treating the coronavirus in a US government study.

But does that make Gilead a good stock to buy now, particularly if you’re focused on income? Let’s take a look.

First up, unlike many other stocks these days, Gilead boasts a safe payout, with the dividend accounting for just 38% of free cash flow in the last 12 months. And the company has increased its dividend every year since initiating it in 2015:

A Reliable Dividend

It’s on the current-yield front where the dividend story starts to fray.… Read more

Read More

What’s better than a portfolio that will pay you a $117,000 salary every year in retirement?

How about one that delivers a consistent paycheck each and every month that you can plan all of your regular expenses around?

I’ll show you how, via with three already-diversified high-yield monthly dividend stocks. But first, let me show you how most income investors get it wrong.

Mistake 1: Cheating Themselves on Yield

Sure, yield isn’t everything—you want growth potential, dividend growth potential and safety, too—but it matters. Consider this: Every 1% in yield equates to $10,000 on a $1 million nest egg. Thus, 2% is $20,000, 3% is $30,000, and so forth.… Read more

Read More

Today I want to show you a beaten-down sector that has a long history of crushing the market—and 4 funds that should be on your radar now.

These 4 funds are a great place to pocket dividends up to 10.9% (or $10,900 a year on a $100k investment) while you wait for the market to realize that it’s discounting their industry far too much.

I’m talking about 4 standout fund buys from the biotech sector.

Biotech has fallen over 10% from its 2018 high and is now down a bit more than the broader market. Just look at the iShares Nasdaq Biotechnology ETF (IBB) vs.…
Read more

Read More

Categories